The claimed invention is:

1. A compound of formula (Ia), (Ib), or (Ic):



(Ia) (Ib)

(Ic)

or a pharmaceutically acceptable salt, prodrug, tautomer, hydrate or solvate thereof, wherein:

R^1 is a saturated, unsaturated, or aromatic C_3-C_{20} mono-, bi- or polycyclic ring optionally containing at least one heteroatom selected from the group consisting of N, O and S, wherein R^1 can optionally be further independently substituted with at least one moiety independently selected from the group consisting of: carbonyl, halo, halo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkyl, perhalo(C_1-C_6)alkoxy, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_2-C_6)alkynyl, hydroxy, oxo, mercapto, (C_1-C_6)alkylthio, (C_1-C_6)alkoxy, (C_5-C_{10})aryl or (C_5-C_{10})heteroaryl, (C_5-C_{10})aryloxy or (C_5-C_{10})heteroaryloxy, (C_5-C_{10})ar(C_1-C_6)alkyl or (C_5-C_{10})heteroar(C_1-C_6)alkyl, (C_5-C_{10})ar(C_1-C_6)alkoxy or (C_5-C_{10})heteroar(C_1-C_6)alkoxy, HO-(C=O)-, ester, amido, ether, amino, amino(C_1-C_6)alkyl, (C_1-C_6)alkylamino(C_1-C_6)alkyl, di(C_1-C_6)alkylamino(C_1-C_6)alkyl, (C_5-C_{10})heterocyclyl(C_1-C_6)alkyl, (C_1-C_6)alkyl- and di(C_1-C_6)alkylamino, cyano, nitro, carbamoyl, (C_1-C_6)alkylcarbonyl,

$(C_1\text{-}C_6)$alkoxycarbonyl, $(C_1\text{-}C_6)$alkylaminocarbonyl, di$(C_1\text{-}C_6)$alkylaminocarbonyl, $(C_5\text{-}C_{10})$arylcarbonyl, $(C_5\text{-}C_{10})$aryloxycarbonyl, $(C_1\text{-}C_6)$alkylsulfonyl, and $(C_5\text{-}C_{10})$arylsulfonyl;

each R^3 is independently selected from the group consisting of: hydrogen, halo, halo$(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, phenyl, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic, $(C_3\text{-}C_{10})$cycloalkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, phenoxy, $(C_5\text{-}C_{10})$heteroaryl-O-, $(C_5\text{-}C_{10})$heterocyclic-O-, $(C_3\text{-}C_{10})$cycloalkyl-O-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-SO_2-, $(C_1\text{-}C_6)$alkyl-NH-SO_2-, O_2N-, NC-, amino, $Ph(CH_2)_{1\text{-}6}HN$-, $(C_1\text{-}C_6)$alkyl HN-, $(C_1\text{-}C_6)$alkylamino, $[(C_1\text{-}C_6)\text{alkyl}]_2$-amino, $(C_1\text{-}C_6)$alkyl-SO_2-NH-, amino(C=O)-, aminoO_2S-, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-[(($(C_1\text{-}C_6)$alkyl)-N]-, phenyl-(C=O)-NH-, phenyl-(C=O)-[($(C_1\text{-}C_6)$alkyl)-N]-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, H_2N(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-(C=O)-, phenyl-NH-(C=O)-, phenyl-[(($C_1\text{-}C_6$)alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)- and $(C_1\text{-}C_6)$alkyl-(C=O)-O-;

where alkyl, alkenyl, alkynyl, phenyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^3 is optionally substituted by at least one substituent independently selected from $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, halo$(C_1\text{-}C_6)$alkyl, halo, H_2N-, $Ph(CH_2)_{1\text{-}6}HN$-, and $(C_1\text{-}C_6)$alkylHN-;

s is an integer from one to five;

and

R^6 is selected from the group consisting of hydrogen, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, phenyl, $(C_5\text{-}C_{10})$heteroaryl, $(C_5\text{-}C_{10})$heterocyclic, $(C_3\text{-}C_{10})$cycloalkyl, $(C_1\text{-}C_6)$alkyl-(SO_2)-, phenyl-(SO_2)-, H_2N-(SO_2)-,

$(C_1\text{-}C_6)$alkyl-NH-(SO_2)-, $((C_1\text{-}C_6)\text{alkyl})_2$N-$(SO_2)$-, phenyl-NH-$(SO_2)$-, $(\text{phenyl})_2$N-(SO_2)-, $(C_1\text{-}C_6)$alkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-O-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-O-(C=O)-, H_2N-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, phenyl-NH-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)-, $((C_1\text{-}C_6)\text{alkyl})_2$N-(C=O)-, $(\text{phenyl})_2$N-(C=O)-, phenyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, and $(C_3\text{-}C_{10})$cycloalkyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-;

where alkyl, alkenyl, alkynyl, phenyl, benzyl, heteroaryl, heterocyclic, cycloalkyl, alkoxy, phenoxy, amino of R^6 is optionally substituted with at least one moiety independently selected from the group consisting of halo, $(C_1\text{-}C_6)$alkyl, $(C_2\text{-}C_6)$alkenyl, $(C_2\text{-}C_6)$alkynyl, perhalo$(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, phenyl, benzyl, $(C_5\text{-}C_{10})$heterocyclic, $(C_5\text{-}C_{10})$heteroaryl, $(C_1\text{-}C_6)$alkyl-SO_2-, formyl, NC-, $(C_1\text{-}C_6)$alkyl-(C=O)-, (C_3C_{10})cycloalkyl-(C=O)-, phenyl-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-, HO-(C=O)-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-O-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-O-(C=O)-, $(C_1\text{-}C_6)$alkyl-NH-(C=O)-, $(C_3\text{-}C_{10})$cycloalkyl-NH-(C=O)-, phenyl-NH-(C=O)-, $(C_5\text{-}C_{10})$heterocyclic-NH-(C=O)-, $(C_5\text{-}C_{10})$heteroaryl-NH-(C=O)-, $((C_1\text{-}C_6)\text{alkyl})_2$-N-(C=O)-, phenyl-[$(C_1\text{-}C_6)$alkyl)-N]-(C=O)-, hydroxy, $(C_1\text{-}C_6)$alkoxy, perhalo$(C_1\text{-}C_6)$alkoxy, $(C_3\text{-}C_{10})$cycloalkyl-O-, phenoxy, $(C_5\text{-}C_{10})$heterocyclic-O-, $(C_5\text{-}C_{10})$heteroaryl-O-, $(C_1\text{-}C_6)$alkyl-(C=O)-O-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-O-, phenyl-(C=O)-O-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-O-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-O-, O_2N-, amino, $(C_1\text{-}C_6)$alkylamino, $((C_1\text{-}C_6)\text{alkyl})_2$-amino, formamidyl, $(C_1\text{-}C_6)$alkyl-(C=O)-NH-, $(C_3\text{-}C_{10})$cycloalkyl-(C=O)-NH-, phenyl-(C=O)-NH-, $(C_5\text{-}C_{10})$heterocyclic-(C=O)-NH-, $(C_5\text{-}C_{10})$heteroaryl-(C=O)-NH-, $(C_1\text{-}C_6)$alkyl-(C=O)-[$(C_1\text{-}C_6)$alkyl)-N]-, phenyl-(C=O)-[$(C_1\text{-}C_6)$alkyl-N]-, $(C_1\text{-}C_6)$alkyl-SO_2NH-, $(C_3\text{-}C_{10})$cycloalkyl-SO_2NH-, phenyl-SO_2NH-,

$(C_5\text{-}C_{10})$heterocyclic-SO_2NH- and $(C_5\text{-}C_{10})$heteroaryl-SO_2NH-;

wherein the phenyl or heteroaryl moiety of a R^6 substituent is optionally further substituted with at least one radical independently selected from the group consisting of halo, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, perfluoro$(C_1\text{-}C_6)$alkyl and perfluoro$(C_1\text{-}C_6)$alkoxy,

with the proviso that R^1 is not a naphthyl or phenyl; and

with the proviso that when R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing up to three N atoms, said N is other than -NH or -N$C_{1\text{-}6}$alkyl or if said N is -NH or -N$C_{1\text{-}6}$alkyl, then R^1 must be further substituted; and

with the proviso that when R^1 is a phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members containing 1-3 heteroatoms independently selected from O and S, then R^1 must be further substituted.

2. A compound of claim 1, wherein R^1 is


,

, or

.

3. A compound of claim 1, wherein R^1 is


,

,

or

.

4. A compound of claim 1, wherein R^1 is



or .

5. A compound of claim 1, wherein R^1 is



,



,



,



,



, or



.

6. A compound of claim 1, wherein R^1 is



,



, or



.

7. A compound of claim 1, wherein R^1 is



,



,



,



or .

8. A compound of claim 1, wherein R^1 is



or

.

9. A compound of claim 1, wherein s is one to two; R^3 is hydrogen or (C_1-C_6)alkyl; and R^6 is H, (C_1-C_6)alkyl, or (C_3-C_{10})cycloalkyl.

10. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

11. A method of preventing or treating a TGF-related disease state in an animal or human comprising the step of administering a therapeutically effective amount of a compound of claim 1 to the animal or human suffering from the TGF-related disease state.

12. A method of claim 11, wherein said TGF-related disease state is selected from the group consisting of cancer, glomerulonephritis, diabetic nephropathy, hepatic fibrosis, pulmonary fibrosis, intimal hyperplasia and restenosis, scleroderma, and dermal scarring.